BRPI0809330B8 - uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica - Google Patents

uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica

Info

Publication number
BRPI0809330B8
BRPI0809330B8 BRPI0809330A BRPI0809330A BRPI0809330B8 BR PI0809330 B8 BRPI0809330 B8 BR PI0809330B8 BR PI0809330 A BRPI0809330 A BR PI0809330A BR PI0809330 A BRPI0809330 A BR PI0809330A BR PI0809330 B8 BRPI0809330 B8 BR PI0809330B8
Authority
BR
Brazil
Prior art keywords
lactic acid
acid oligomers
infection
pharmaceutical composition
hpv
Prior art date
Application number
BRPI0809330A
Other languages
English (en)
Portuguese (pt)
Inventor
Sjögren Christer
Batcheller Greg
Johnsson Jörgen
Sznitowska Malgorzat
Sterner Olov
Hedner Thomas
Schubert Werner
Original Assignee
Laccure Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laccure Ab filed Critical Laccure Ab
Publication of BRPI0809330A2 publication Critical patent/BRPI0809330A2/pt
Publication of BRPI0809330B1 publication Critical patent/BRPI0809330B1/pt
Publication of BRPI0809330B8 publication Critical patent/BRPI0809330B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0809330A 2007-03-30 2008-03-28 uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica BRPI0809330B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200700508 2007-03-30
DKPA200700508 2007-03-30
PCT/EP2008/002505 WO2008119518A1 (en) 2007-03-30 2008-03-28 Use of oligomers of lactic acid in the treatment of gynaecological disorders

Publications (3)

Publication Number Publication Date
BRPI0809330A2 BRPI0809330A2 (pt) 2014-09-09
BRPI0809330B1 BRPI0809330B1 (pt) 2019-12-17
BRPI0809330B8 true BRPI0809330B8 (pt) 2021-05-25

Family

ID=39494560

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809330A BRPI0809330B8 (pt) 2007-03-30 2008-03-28 uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica

Country Status (19)

Country Link
US (3) US8425894B2 (enExample)
EP (2) EP2679222A1 (enExample)
JP (2) JP5409596B2 (enExample)
KR (1) KR101518014B1 (enExample)
CN (2) CN103830216B (enExample)
AU (1) AU2008234064B2 (enExample)
BR (1) BRPI0809330B8 (enExample)
CA (1) CA2681803C (enExample)
CY (1) CY1115310T1 (enExample)
DK (1) DK2142186T3 (enExample)
ES (1) ES2482190T3 (enExample)
HR (1) HRP20140559T1 (enExample)
MX (1) MX2009010445A (enExample)
PL (1) PL2142186T3 (enExample)
PT (1) PT2142186E (enExample)
RU (1) RU2459620C2 (enExample)
SI (1) SI2142186T1 (enExample)
WO (1) WO2008119518A1 (enExample)
ZA (1) ZA200907215B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2459620C2 (ru) 2007-03-30 2012-08-27 Лаккуре Аб Применение олигомеров молочной кислоты в лечении гинекологических расстройств
CN101797269B (zh) * 2010-03-23 2012-01-04 杨霞 一种调节女性阴道微生态的生理平衡液
RU2422147C1 (ru) * 2010-03-29 2011-06-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ лечения неспецифического аэробного вагинита
WO2012158779A1 (en) 2011-05-17 2012-11-22 Reprotect, Inc. Reusable intravaginal delivery device, system, and method
CN102274333A (zh) * 2011-08-22 2011-12-14 谢英华 一种治疗阴道炎的外洗中药
CN102579829B (zh) * 2012-03-06 2013-09-18 康莉 一种治疗牛放线菌病的中药组合物及其制备方法
WO2013187984A1 (en) 2012-06-13 2013-12-19 Evofem, Inc. Compositions and methods for enhancing the efficacy of contraceptive microbicides
BR112015001006B1 (pt) * 2012-07-16 2022-05-17 Laccure Ab Composição que compreende ácido lático oligomérico, e método para a preparação da composição
CN102885850B (zh) * 2012-10-15 2013-08-07 山东省医疗器械研究所 一种治疗阴道炎的多孔凝胶颗粒剂
NZ722215A (en) 2013-12-19 2019-02-22 Evofem Inc Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
US9895311B2 (en) * 2014-09-25 2018-02-20 Pharmiva Ab Foam-forming compositions and methods for delivering an active to a body cavity
DK3439633T3 (da) 2016-04-06 2021-12-20 Gedea Biotech Ab Glucono delta-lacton til behandling af vaginale svampeinfektioner
US10249017B2 (en) * 2016-08-11 2019-04-02 Intel Corporation Apparatus and method for shared resource partitioning through credit management
US20190209502A1 (en) * 2016-09-12 2019-07-11 Evofem, Inc. Combination gel for sexually transmitted infections
AU2017338748A1 (en) 2016-10-04 2019-05-02 Evofem Inc. Method of treatment and prevention of bacterial vaginosis
JP7219712B2 (ja) * 2016-10-13 2023-02-08 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 膣送達のための凍結乾燥医薬組成物
LT3773501T (lt) * 2018-03-29 2024-01-10 The Materia Company Limited Intravaginalinis preparatas
US20220096349A1 (en) * 2019-02-13 2022-03-31 Miyoshi Oil & Fat Co., Ltd. Cosmetic compounding agent, cosmetic and production method thereof
WO2023165971A1 (en) 2022-03-01 2023-09-07 Laccure Ab Process for preparation of compositions of oligomers of lactic acid
EP4590289A4 (en) * 2023-07-07 2025-11-26 Changchun Sinobiomaterials Co Ltd MUSCLE ATROPHY

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431427A (en) * 1981-10-05 1984-02-14 University Of Delaware Tampons and their manufacture
US5274127A (en) * 1990-09-18 1993-12-28 Biopak Technology, Ltd. Lactide production from dehydration of aqueous lactic acid feed
JP2919912B2 (ja) 1990-05-23 1999-07-19 鐘紡株式会社 修飾プロテアーゼ及びその製造法
US5142023A (en) * 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
JPH07132127A (ja) 1993-06-17 1995-05-23 Mitsui Toatsu Chem Inc 生理用ナプキン
DE19506395A1 (de) 1994-02-24 1995-08-31 Ecological Chem Prod Zusammensetzung und Verfahren zum Verpacken feuchtigkeitshaltiger Lebensmittel
US5521278A (en) * 1994-08-18 1996-05-28 Ecological Chemical Products Integrated process for the manufacture of lactide
JP2864218B2 (ja) 1994-12-06 1999-03-03 株式会社日本製鋼所 ポリ乳酸共重合体の製造方法
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
JPH09227388A (ja) * 1996-02-15 1997-09-02 Naganushi Tetsuaki 大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤
AU2459497A (en) 1996-05-31 1998-01-05 Research And Development Institute, Inc. Urinary medical devices
US6229046B1 (en) 1997-10-14 2001-05-08 Cargill, Incorported Lactic acid processing methods arrangements and products
JP2000072680A (ja) * 1998-08-25 2000-03-07 Shiyumeidou:Kk 免疫機能調節剤
JP2001139476A (ja) * 1999-11-15 2001-05-22 Youichirou Naganushi 癌を含めた悪性新生物に用いる抗悪性腫瘍剤
RU2163810C1 (ru) * 2000-05-18 2001-03-10 Майорова Нина Федоровна Состав для удаления доброкачественных новообразований на коже и слизистых и способ его получения
WO2002055090A1 (fr) * 2001-01-12 2002-07-18 Amato Pharmaceutical Products,Ltd. Agents preventifs d'infections microbiennes
EP1362594A1 (en) 2001-01-24 2003-11-19 Amato Pharmaceutical Products, Ltd. Anti-stress agents
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
JP2002275256A (ja) * 2001-03-19 2002-09-25 Tendou Seiyaku Kk 乳酸オリゴマーの製造方法
WO2003016259A2 (de) 2001-08-16 2003-02-27 Pharmacon-Forschung Und Beratung Gmbh Milchsäureelemente enthaltende verbindungen, deren herstellung sowie deren verwendung als pharmazeutische wirkstoffe
WO2003039560A1 (en) * 2001-11-06 2003-05-15 Amato Pharmaceutical Products, Ltd. Antitumor agent containing lactic acid oligomer mixture
JP2004307561A (ja) * 2003-04-02 2004-11-04 Tendou Seiyaku Kk 環状乳酸オリゴマーの製造方法
CA2523740C (en) 2003-05-01 2012-05-15 Innogene Kalbiotech Pte Ltd Lactate containing pharmaceutical composition and uses thereof
JP4316299B2 (ja) * 2003-06-03 2009-08-19 学校法人東海大学 鎖状乳酸オリゴマー誘導体およびその製造方法
JP2005126361A (ja) * 2003-10-23 2005-05-19 Tendou Seiyaku Kk ポリ乳酸混合物を含むマトリックスメタロプロテアーゼ抑制剤
CN1562049A (zh) * 2004-04-02 2005-01-12 聂四平 低聚果糖在制备治疗及预防阴道炎药中的应用
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
SE528337C2 (sv) 2004-06-23 2006-10-24 Nestor Medical Ab Sammansättning innefattande mjölksyra och laktoferrin, eller ett peptidfragment därav, och användning av denna sammansättning för behandling av tillstånd i urogenitalsystemet
JP2006232909A (ja) * 2005-02-23 2006-09-07 Tokai Univ 環状オリゴ乳酸
JP4431102B2 (ja) 2005-11-11 2010-03-10 キャタピラージャパン株式会社 カウンタウエイト及びカウンタウエイトの製造方法並びに作業機械
RU2308970C1 (ru) * 2006-03-10 2007-10-27 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Антибактериальное средство для лечения внутриклеточных инфекций
JP2007258526A (ja) 2006-03-24 2007-10-04 Konica Minolta Holdings Inc 有機エレクトロルミネッセンス素子、及び有機エレクトロルミネッセンスディスプレイ
JP2008157576A (ja) 2006-12-26 2008-07-10 Sharp Corp 加湿機
RU2459620C2 (ru) 2007-03-30 2012-08-27 Лаккуре Аб Применение олигомеров молочной кислоты в лечении гинекологических расстройств

Also Published As

Publication number Publication date
KR101518014B1 (ko) 2015-05-06
US8425894B2 (en) 2013-04-23
MX2009010445A (es) 2010-01-29
JP2010523480A (ja) 2010-07-15
US9315444B2 (en) 2016-04-19
PL2142186T3 (pl) 2014-09-30
AU2008234064A1 (en) 2008-10-09
PT2142186E (pt) 2014-07-17
EP2142186B1 (en) 2014-04-30
CN103830216A (zh) 2014-06-04
HRP20140559T1 (hr) 2014-08-01
CN101677980B (zh) 2013-10-23
CY1115310T1 (el) 2017-01-04
KR20100016060A (ko) 2010-02-12
JP5793542B2 (ja) 2015-10-14
ZA200907215B (en) 2014-03-26
EP2679222A1 (en) 2014-01-01
DK2142186T3 (da) 2014-08-04
BRPI0809330B1 (pt) 2019-12-17
RU2009140141A (ru) 2011-05-10
CN103830216B (zh) 2016-08-17
CA2681803C (en) 2014-08-05
EP2142186A1 (en) 2010-01-13
ES2482190T3 (es) 2014-08-01
JP2014012675A (ja) 2014-01-23
US20130317104A1 (en) 2013-11-28
CN101677980A (zh) 2010-03-24
WO2008119518A1 (en) 2008-10-09
US20110020265A1 (en) 2011-01-27
CA2681803A1 (en) 2008-10-09
RU2459620C2 (ru) 2012-08-27
BRPI0809330A2 (pt) 2014-09-09
AU2008234064B2 (en) 2013-02-07
JP5409596B2 (ja) 2014-02-05
US20150025142A1 (en) 2015-01-22
SI2142186T1 (sl) 2014-08-29
US8912232B2 (en) 2014-12-16

Similar Documents

Publication Publication Date Title
BRPI0809330B8 (pt) uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica
Krylova et al. The comparative analysis of antiviral activity of native and modified fucoidans from brown algae Fucus evanescens in vitro and in vivo
BRPI0705319A2 (pt) processo para obtenção de um complexo solúvel de resveratrol e/ou seus derivados; complexo de resveratrol e/ou seus derivados; composição nutracêutica
CL2008000863A1 (es) Compuestos derivados de 9-pirimidin-4-il-1-oxa-3,9-diaza-espiro(5.5)undecan-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar o prevenir la infeccion del virus vih, artritis reumatoide, asma, enfermedad pulmonar obstructiva congestiva y el rechazo de transplantes de organos solidos.
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
CY1113949T1 (el) Αντιιικη συνθεση, η οποια περιεχει εναν θειικο πολυσακχαριτη: ι-καρραγενανη
BR112017018022A2 (pt) "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
FI4108671T3 (fi) Muokattuja nukleosideja, nukleotideja ja nukleiinihappoja sekä niiden käyttötapoja
BR112017023263A2 (pt) compostos antivirais rsv de pirazolo e triazolopirimidina
UY33600A (es) Análogos de carba-nucleósidos 2` - flúor sustituidos para tratamiento antiviral y uso de los mismos en la preparación de medicamentos
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
UY32673A (es) Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
BR112021024063A2 (pt) Identificação e seleção de um material de partida vegetal de sulfato de condroitina vegetal e ácido hialurônico, e transformação de tal material de partida vegetal para obter ingredientes para uso em alimentos, suplementos, dispositivos médicos ou fármacos
BR112013015149A2 (pt) composição para solubilização de um fluoropolímero, composição de fluoropolímero combinação de solventes, processos de preparação de uma composição, uso da composição de fluoropolímero, processo para revestimento de um substrato e uso da combinação de solventes
GB201203582D0 (en) Sulfonamide-containing photoresist compositions and methods of use
AR063747A1 (es) Definilazetidinona sustituida con acido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas
AR088963A1 (es) Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina
UY37086A (es) Moléculas que tienen utilidad plaguicida y productos intermedios, composiciones y procesos, relacionados con las mismas
AR113808A1 (es) Método para la preparación de compuestos intermedios de azoxistrobina
CO2019008987A2 (es) Mejoras en o con respecto a compuestos orgánicos
BR112014013573A2 (pt) materiais alcoxilados com baixo teor de bisfenol a residual, sua preparação e uso dos mesmos
BR112017019750A2 (pt) processo para preparação de uma forma cristalina de menaquinol, forma cristalina de menaquinol, processo para preparação de uma forma sólida do menaquinol, composição farmacêutica ou nutracêutica e uso da forma cristalina de menaquinol
BRPI0814725B8 (pt) uso da composição antiviral
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/03/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF